Germany’s EVANIUM Secures €2.2 Million to Enhance Nutraceutical Efficacy

Introduction

In an exciting development for the life-science sector, Regensburg-based startup EVANIUM has successfully closed a €2.2 million Seed funding round. This significant investment, led by FoodLabs and Feast Ventures with contributions from existing angel investors, marks a pivotal moment for the company. EVANIUM is set to revolutionize the nutraceutical industry with its proprietary OPTISOLV® technology, designed to enhance the solubility and bioavailability of nutraceutical ingredients. But what does this mean for the industry and consumers alike?

Breaking Down the Innovation

Founded in 2019 by Felix Rolka, David Ofner, and Carlo Werkmann, EVANIUM has positioned itself at the forefront of innovation in nutraceuticals, functional foods, nutricosmetics, and pharmaceuticals. The company's OPTISOLV® technology stands out by addressing a critical inefficiency: the poor absorption of active ingredients in many supplements. Despite high costs, these products often fail to deliver their promised benefits due to low bioavailability.

OPTISOLV® employs a unique dual-coating system combining a cyclodextrin-based core with an outer phospholipid shell. This structure stabilizes natural actives in a crystal-free, highly dispersible state, significantly improving solubility and absorption. For challenging ingredients like Curcumin, EVANIUM reports that their technology boosts solubility by over 1,000 times and release during digestion by more than 170 times compared to traditional methods.

Strategic Growth and Market Impact

With the new funding, EVANIUM aims to scale its OPTISOLV® technology, expand its team, advance clinical studies, and forge commercial partnerships. These efforts will enable the development of high-performance, clean-label products that truly deliver on their health promises. According to Adrian Friederich, Head of Investments at FoodLabs, this advancement doesn't just benefit brands; it directly improves consumer outcomes.

EVANIUM’s collaboration with Hevert-Arzneimittel to release OPTISOLV® Curcumin in 2025 marked the company's initial commercial launch in Germany, establishing the technology's market readiness. The company has since filed its fourth patent, solidifying OPTISOLV® as the cornerstone of a scalable ingredient platform. The portfolio now includes four functional ingredients: Curcumin, Berberine, Boswellia, and Passiflora, with further clinical studies planned to enhance scientific validation.

Insights for Startups and Investors

For startups and investors, EVANIUM's journey highlights the importance of addressing fundamental inefficiencies within an industry. By focusing on technological innovation, the company has not only carved out a unique niche but also set a new standard for product efficacy in the nutraceutical market. The emphasis on smarter formulations rather than higher dosages represents a shift towards more sustainable and consumer-friendly solutions.

Conclusion

EVANIUM's €2.2 million funding round is more than just a financial milestone; it’s a testament to the potential of innovative startups to disrupt established industries. As the company continues to grow, its impact on the nutraceutical industry could redefine how consumers perceive and utilize supplements. The future of nutraceuticals indeed lies in smarter, more effective formulations, and EVANIUM is at the helm of this transformative wave.

Source: EU-Startups